Cargando…

Prognostic Markers of Myelodysplastic Syndromes

Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid leukemia. In theory, from clonal hematopoiesis of indeterminate potential to hematologic malignancies, there is a complex interp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veryaskina, Yuliya Andreevna, Titov, Sergei Evgenievich, Kovynev, Igor Borisovich, Pospelova, Tatiana Ivanovna, Zhimulev, Igor Fyodorovich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466347/ https://www.ncbi.nlm.nih.gov/pubmed/32727068 http://dx.doi.org/10.3390/medicina56080376

Ejemplares similares

The miRNA Profile in Non-Hodgkin’s Lymphoma Patients with Secondary Myelodysplasia
por: Veryaskina, Yuliya Andreevna, et al.
Publicado: (2020)

Reference Genes for qPCR-Based miRNA Expression Profiling in 14 Human Tissues
por: Veryaskina, Yulia Andreevna, et al.
Publicado: (2022)

MicroRNAs in the Myelodysplastic Syndrome
por: Veryaskina, Y. A., et al.
Publicado: (2021)

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas
por: Veryaskina, Yuliya A., et al.
Publicado: (2022)

MicroRNA Expression Profile in Bone Marrow and Lymph Nodes in B-Cell Lymphomas
por: Veryaskina, Yuliya A., et al.
Publicado: (2023)

Profiling 25 Bone Marrow microRNAs in Acute Leukemias and Secondary Nonleukemic Hematopoietic Conditions
por: Kovynev, Igor B., et al.
Publicado: (2020)

Selection of reference genes for quantitative analysis of microRNA expression in three different types of cancer
por: Veryaskina, Yuliya A., et al.
Publicado: (2022)

Intratumoral Heterogeneity of Expression of 16 miRNA in Luminal Cancer of the Mammary Gland
por: Veryaskina, Yuliya A., et al.
Publicado: (2020)

Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears
por: Titov, Sergei E., et al.
Publicado: (2019)

Diagnostics and Prognostication of Myelodysplastic Syndromes
por: Zini, Gina
Publicado: (2017)

EnvIRONmental Aspects in Myelodysplastic Syndrome
por: Petzer, Verena, et al.
Publicado: (2021)

The Evolving Landscape of Myelodysplastic Syndrome Prognostication
por: Shreve, Jacob, et al.
Publicado: (2020)

miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors
por: Titov, Sergei E., et al.
Publicado: (2016)

Cytological and molecular diagnosis of Hürthle cell thyroid tumors: Analysis of three cases
por: Titov, Sergei E., et al.
Publicado: (2021)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome
por: Botezatu, Lacramioara, et al.
Publicado: (2016)

Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
por: Blau, Olga, et al.
Publicado: (2014)

Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility
por: Shahjahani, Mohammad, et al.
Publicado: (2019)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
por: Wang, Fei, et al.
Publicado: (2013)

Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients
por: He, Rong, et al.
Publicado: (2022)

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
por: Cook, Michael R., et al.
Publicado: (2021)

Signal transduction inhibitors in treatment of myelodysplastic syndromes
por: Bachegowda, Lohith, et al.
Publicado: (2013)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems
por: Bektaş, Özlen, et al.
Publicado: (2016)

Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes – A potential prognostic marker?
por: Book, Reut, et al.
Publicado: (2023)

The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications
por: Awada, Hassan, et al.
Publicado: (2020)

Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
por: Parisi, Sarah, et al.
Publicado: (2021)

Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021)

Routine Inflammatory Markers Are Elevated in Myelodysplastic Syndromes at Presentation
por: Oster, Howard S., et al.
Publicado: (2023)

Genetic basis of myelodysplastic syndromes
por: OGAWA, Seishi
Publicado: (2020)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

Hereditary Predispositions to Myelodysplastic Syndrome
por: Bannon, Sarah A., et al.
Publicado: (2016)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Myelodysplastic Syndrome: Diagnosis and Screening
por: Tria, Francisco P., et al.
Publicado: (2022)

The Mesenchymal Niche in Myelodysplastic Syndromes
por: Friedrich, Chloé, et al.
Publicado: (2022)

Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
por: Sotirova, Tatjana, et al.
Publicado: (2014)

Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome
por: Shi, Cong, et al.
Publicado: (2022)

The benefits of navigated neuroendoscopy in children with multiloculated hydrocephalus
por: Kim, Sergei Afanasievich, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_55gg0e56e0sap5ddelkt6ie4pq